Impact of COVID ‐19 on long‐term outcomes in Parkinson's disease
European Journal of Neurology · 2025
DOI: 10.1111/ene.70013 ↗At a glance
Journal article in European Journal of Neurology, 2025. Written by Roham Hadidchi and 9 co-authors. Institution: Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA. Major MEDLINE topics: Parkinson Disease, COVID-19. Cited 18 times so far (Crossref); 70 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Objectives
Patients with pre‐existing Parkinson's disease (PD) face higher risks of severe acute COVID‐19 outcomes than matched controls, but long‐term post‐COVID‐19 outcomes remain largely unknown. This study investigated clinical outcomes up to 3.5 years post‐infection in a Bronx inner‐city PD population.
Methods
This retrospective study evaluated 3512 patients with PD in the Montefiore Health System (January 2016–July 2023), which serves a large diverse population and was an epicenter of the early COVID‐19 pandemic and subsequent infection surges. Comparisons were made with PD patients without a positive SARS‐CoV‐2 test (defined by polymerase chain reaction test). Outcomes were post‐index date all‐cause mortality, major adverse cardiovascular events (MACE), altered mental status, fatigue, dyspnea, headache, psychosis, dementia, depression, anxiety, dysphagia, falls, and orthostatic hypotension. Changes in Levodopa prescriptions were also tabulated. Adjusted hazard ratios (aHR) were computed accounting for competing risks.
Results
PD patients with COVID‐19 had similar demographics but a higher prevalence of pre‐existing comorbidities compared to PD patients without COVID‐19. PD patients with COVID‐19 had greater risk of mortality (aHR = 1.58 [95% CI: 1.03, 2.41]), MACE (aHR = 1.57 [1.19, 2.07]), dyspnea, fatigue, and fall compared to PD patients without COVID‐19. Levodopa dose adjustment was higher post‐infection in the COVID‐19 cohort.
Conclusions
Among PD patients, COVID‐19 was associated with a higher risk of adverse long‐term outcomes. PD patients who survive COVID‐19 may benefit from heightened clinical awareness and close follow‐up. Findings highlight the need to improve post‐COVID care for PD patients to mitigate disease progression and maintain quality of life.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Radiology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
- Department of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Neurology, Stony Brook University Renaissance School of Medicine, Stony Brook, New York, USA.
- Center for Health and Data Innovation, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
ORCID profiles: Tim Q Duong
Cite
APA
Hadidchi, R., Al-Ani, Y., Piskun, H., Pakan, R., Duong, K. S., Jamil, H., Wang, S. H., Henry, S., Maurer, C. W., & Duong, T. Q. (2025). Impact of COVID ‐19 on long‐term outcomes in Parkinson's disease. European Journal of Neurology. https://doi.org/10.1111/ene.70013
Vancouver
Hadidchi R, Al-Ani Y, Piskun H, Pakan R, Duong KS, Jamil H, et al. Impact of COVID ‐19 on long‐term outcomes in Parkinson's disease. European Journal of Neurology. 2025. doi:10.1111/ene.70013
BibTeX
@article{Hadidchi2025,
author = {Hadidchi, Roham and Al-Ani, Yousef and Piskun, Hannah and Pakan, Rachel and Duong, Katie S and Jamil, Hasan and Wang, Stephen H and Henry, Sonya and Maurer, Carine W and Duong, Tim Q},
title = {Impact of COVID ‐19 on long‐term outcomes in Parkinson's disease},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70013}
}
EUVIMED